top of page
  • europevaccine

Shigella prevalence baseline study selected to be presented at the ASTMH annual meeting 2022

The ShigaPlexIM abstract titled "Prevalence of bacterial and parasitic enteropathogens in children under five during a high transmission period in a community setting in Ouagadougou, Burkina Faso" has been selected for poster presentation at the American Society of Tropical Medicine and Hygiene (ASTMH) 2022 annual meeting, which will take place between the 30th of October and the 3rd of November.

Dr. Flavia D'Alessio is attending the ASTMH conference to represent European vaccine Initiative (EVI).

ShigaPlexIM is a collaborative project funded by the European & Developing Countries Clinical Trials Partnership (EDCTP2) Programme supported by the European Union. The project is the joint effort of leading African and European experts with proven track records in research and development of vaccines against poverty-related neglected diseases, including diarrhoeal diseases.

According to WHO diarrhoea kills 446.000 children under 5 in sub-Saharan Africa and South Asia. In 2016, Shigella caused 212.000 deaths and 13% of all diarrhoea-related deaths. It kills between 28.000-64.000 children under 5 in low- and middle-income countries (LMICs) every year.

Under ShigaPlexIM project, an epidemiological baseline study was conducted at Groupe de Recherche Action Santé (GRAS), Burkina Faso, to assess the prevalence of Shigella and other enteric bacterial infections in children under five presenting with Severe-to-Moderate Diarrhoea (SMD). The results of this study will support the design of future efficacy trials for Shigella vaccine candidates.


bottom of page